You could say that about 99% if penny stocks. It's
Post# of 30027
(Total Views: 466)
Posted On: 01/05/2018 2:41:16 PM
You could say that about 99% if penny stocks. It's high risk, high rewards. The chances of what any CEO says in any of those stocks is likely not to come true. It's why every presentation done at every company has that disclaimer. I knew that going in. With any of these penny stocks, if there is a date something is going to happen I double it and assume chances are it won't. Keeps me from getting my hopes up too high.
What's Amarantus's batting average? I don't know. Maybe 50%. A lot of bunts and singles, but no home runs and or runs scored. I can think of many times the company said they were going to do something and they did. But there are many other times it didn't pan out. There is a difference between will and want.
Being in the bio business you know this and one of the reasons why you, unlike a few others, didn't make it their career to whine on a messageboard and smart enough to step away. What a waste of a life for them and they do it on holiday's too.
"Dad, the turkey is getting cold"
"Just a dam minute, can't you see I'm busy on my commodore 64. I'm trying to post another one of those mymy things and it's taking forever"
So sad, too bad.
Getting back to the worthless Elto. If that was the case, then Dr. Lowe really tricked the company bring it to them. If that were the case, the company really tricked the FDA when they said they WOULD apply for orphan designation for Elto and they DID receive it.
But people hear what they want to here and would have taken that as the company WILL get orphan designation. Chances were not likely, but they did.
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
Feb 10, 2016
https://www.prnewswire.com/news-releases/amar...96831.html
The fact of the matter is it's not easy to get orphan designations and the company as multiple. It's not easy to get patents, but the company has a boat load. Has that sent the stock to $100, obviously not, but at least in the last year, they haven't been sitting on their thumbs wondering what to do.
As far as no studies being done on worthless Elto in the last 10 years all it a takes is a 2 second google search to fine them. Here's a one.
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
2013 Feb 6.
https://www.ncbi.nlm.nih.gov/pubmed/23389842
One may say - well that was from 4 years ago. That fits the window of the last 10 years. It's the first one I pulled up. I could post others but I'm not here to prove the value to the assets to every one. Just myself..
The more recent studies I've read in the last few years are from Europe and not always in English. I rarely have time to search private research portals which I assume you have access to. There is more in there.
You're a smart level headed poster so don't take any of this as aimed at you. Wish most people can be somewhere in the middle between the CEO is a liar and this is going to the moon on the 10th.
What's Amarantus's batting average? I don't know. Maybe 50%. A lot of bunts and singles, but no home runs and or runs scored. I can think of many times the company said they were going to do something and they did. But there are many other times it didn't pan out. There is a difference between will and want.
Being in the bio business you know this and one of the reasons why you, unlike a few others, didn't make it their career to whine on a messageboard and smart enough to step away. What a waste of a life for them and they do it on holiday's too.
"Dad, the turkey is getting cold"
"Just a dam minute, can't you see I'm busy on my commodore 64. I'm trying to post another one of those mymy things and it's taking forever"
So sad, too bad.
Getting back to the worthless Elto. If that was the case, then Dr. Lowe really tricked the company bring it to them. If that were the case, the company really tricked the FDA when they said they WOULD apply for orphan designation for Elto and they DID receive it.
But people hear what they want to here and would have taken that as the company WILL get orphan designation. Chances were not likely, but they did.
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
Feb 10, 2016
https://www.prnewswire.com/news-releases/amar...96831.html
The fact of the matter is it's not easy to get orphan designations and the company as multiple. It's not easy to get patents, but the company has a boat load. Has that sent the stock to $100, obviously not, but at least in the last year, they haven't been sitting on their thumbs wondering what to do.
As far as no studies being done on worthless Elto in the last 10 years all it a takes is a 2 second google search to fine them. Here's a one.
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
2013 Feb 6.
https://www.ncbi.nlm.nih.gov/pubmed/23389842
One may say - well that was from 4 years ago. That fits the window of the last 10 years. It's the first one I pulled up. I could post others but I'm not here to prove the value to the assets to every one. Just myself..
The more recent studies I've read in the last few years are from Europe and not always in English. I rarely have time to search private research portals which I assume you have access to. There is more in there.
You're a smart level headed poster so don't take any of this as aimed at you. Wish most people can be somewhere in the middle between the CEO is a liar and this is going to the moon on the 10th.
(11)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼